Background: The third 90-90-90 UNAIDS goal require that 90% of people living with HIV (PLHIV) on 25 antiretroviral treatment (ART) achieve viral load (VL) suppression. This study assessed the proportion of VL 26 suppression and related factors among PLHIV on 1 st and 2 nd line ART in Mutare District, Manicaland Province, 27 Zimbabwe between 2015-2017. Of 16,590 registered patients, 15,566(94%) were on first-line and 1024(6%) on second-line ART. Of 31 those on 1 st -line ART, 2856(18%) had a VL test result documented, while 367(36%) of 2 nd -line ART patients had 32 VL results. VL suppression rates were 86% among those on 1 st -line and 45% in 2 nd -line ART. Independent risk 33 factors associated with VL non-suppression for those on 1 st -line ART were age 0-9 years (adjusted relative risk, 34 aRR=2.9; 95% confidence interval, CI=1.7-4.8;P<0.001), 10-19 years (aRR=2.2;95%CI=1.4-3.2,P<0.001) 35 compared to those 20-49 years, concurrent TB (aRR=9; CI=3.0-29.7,P<0.001) and male gender 36 (aRR=1.5,95%CI=1.1-2.1;P=0.02). There were no significant risk factors associated with VL non-suppression for 37 2 nd -line ART patients. 38 Conclusion: For PLHIV on 1 st -line ART in Mutare district, Manicaland, Zimbabwe, the frequency of 39 reported VL results were only 18% among those on 1 st -line ART, while the rate of VL suppression was near 90%.
Association, Odense, Denmark) analysed and presented in frequencies for categorical data and continuous 16 variables were categorised for further analysis. Proportion with/without viral load suppression was presented with 17 95% confidence intervals (CIs). Factors associated with non-suppression of viral load were assessed using chi-18 square test at bivariate level and log-binomial regression at multivariate level (using Stata/SE 14.1, StataCorp, 19 College Station, TX, USA). Only variables significant at bivariate level and those which improved the fit of the 20 models to the data were included in the final models. Relative Risks (RRs) were used to calculate the measures of 21 association, and presented with their 95% CIs. Levels of significance were set at ≤ 5%. 
Results

28
There were 16590 patients registered within the 9 Mutare District health facilities between January 2015 -29 December 2017, of whom 15,566 (94%) were on first line and 1,024 (6%) on second line ART regimens. Of those 30 on 1 st line ART, 2856(18%) had a VL test results documented, while 367(36%) of 2 nd line ART patients had VL 31 results, see (Fig 1) . Those patients on 2 nd line therapy were significantly younger compared with those on a 1 st line 32 regimen (38 years (interquartile range, IQR: 19-48) vs 43 years (IQR 35-50), P<0.001), more likely to be female 33 (55% vs 33%, P<0.001) and single (30% vs 17%, P<0.001) see Table 1 . Log-binomial regression analysis was completed to determine the independent strength of risk factor association 51 with viral load non-suppression among those on 1 st line ART, see increased programmatic focus on patients with these risk factors is needed to reduce the frequency of VL non-74 suppression.
75
The findings are unique because they provide "real-world" field perspective into the successes and challenges still 76 facing a remote province in southern Zimbabwe and are likely comparable in other parts of the country and 77 similar contexts elsewhere. The strengths of this study include the use of a district-wide implemented electronic 78 patient monitoring tool for data sourcing and support from collaborative partners for VL sample transport, VL 79 platform resources and medication supply.
80
The primary limitation is the lack of reported viral load results for both 1 st and 2 nd line ART patients which 81 directly limits the ability to determine the true rate of VL suppression. There are likely several reasons for the lack 82 of VL results being documented. First, there is a single VL platform based at Mutare Provincial Hospital (MPH).
83
The MPH lab is the sole provider of all VL results for ART patients in both Manicaland (population 1.7 million) 84 and Masvingo (population 1.5 million). (15) of Manicaland. However, the lack of adequate VL testing coverage appears to be of significant concern on 08 multiple levels. These results suggest that there is an urgent need for increased support for the Zimbabwe VL 09 scale-up plan from collaborative partners which should likely target multiple components of testing system.
10
Further study is needed determine exactly where the greatest gaps are in VL scale-up and our findings must serve 11 as a call for others to assist in this effort. It is highly likely that these challenges in viral load monitoring are not 12 isolated to Mutare district or to Zimbabwe alone. 
